BACKGROUND A concern for new compounds in fertility treatment is the possible risk of perinatal complications or birth defects. To demonstrate long-term safety of ganirelix (GnRH antagonist) treatment in controlled ovarian stimulation (COS), follow-up data on pregnancy and neonatal outcome were analysed for 1000 fetuses (>or=16 gestational weeks). METHODS Obstetrical and neonatal data on 839 ...

CONTEXT AND OBJECTIVE Administration of a gonadotropin-releasing hormone (GnRH) agonist at the preovulatory phase is an option for triggering ovulation in assisted reproductive technology cycles. The aim of this work was to investigate the pattern of prolactin secretion after the administration of a single dose of GnRH-agonist at the preovulatory phase. DESIGN AND SETTING Descriptive study at...

Background: The objective of this study is to evaluate the progesterone level (P Level) on the day of HCG triggering in GnRh agonist and antagonist protocols, and its correlation with clinical pregnancy rate and miscarriage rate. Premature luteinization during in vitro fertilization (IVF) was commonly happened before the introduction of GnRh analogues. High level of unwanted progesterone that i...

BACKGROUND Anti-Müllerian hormone (AMH) is a marker of the ovarian reserve with promising prognostic potential in reproductive medicine. We aimed to evaluate the prognostic ability of AMH for predicting excessive or poor responses to ovarian stimulation using gonadotrophin-releasing hormone (GnRH) agonist and GnRH antagonist protocols in patients undergoing medically assisted reproduction (MAR)...

background: the purpose of present study was to evaluate the role of pre-ovulatory gnrh agonist therapy on ivf outcomes in gnrh antagonist cycles. methods: in this prospective study we recruited 100 infertile women undergoing ivf cycles with gnrh antagonists. the patients were assigned to two groups: group a (the study group, n=42) were assigned for receiving hcg+triptorelin for the final oocyt...

The role of estrogens is dual: they suppress basal expression of gonadotropins and enhance GnRH responsiveness at the time of the LH surge. Estrogens are synthesized by cytochrome P450 aromatase (P450arom), encoded by the cyp19 gene. We focused on the cyp19 gene in rat and showed that it is expressed in gonadotropes through promoters PII and PI.f, using RT-PCR and dual fluorescence labeling wit...

BACKGROUND During in vitro fertilization (IVF), fertility patients are expected to self-administer many injections as part of this treatment. While newer medications have been developed to substantially reduce the number of these injections, such agents are typically much more expensive. Considering these differences in both cost and number of injections, this study compared patient preferences...

Background: Based on classical two cell- two-gonadotropin theory, in the follicle, FSH and LH put on their main effects on the granulosa and theca cells. LH is essential for androgens production. Androgens as precursor, is used for estradiol production by granulosa cells under aromatase activity. Profound suppression of LH concentrations in some normogonadotropic patients can cause several adve...

Sir, We read with great interest the manuscript by Humaidan et al. (2011). In this review, the authors summarize the published evidence regarding the use of GnRH agonist for triggering final oocyte maturation in patients undergoing IVF. By combining the results of six recently published randomized controlled trials (RCTs), the authors suggest that when a modified luteal phase support (LPS) is e...

Since 1981, GnRH agonist administration has been the treatment of choice for central precocious puberty. Continuous administration of the agonist, instead of permanently stimulating gonadotropin secretion, deeply suppresses LH and FSH levels and induces a marked inhibition of gonadal activity and regression of clinical symptoms. This inhibitory effect is due both to specific kinetic parameters ...